The scientific translation of graphene-primarily based nanomaterials in biomedicine remains constrained by means of limited oxidative stability and inadequate multifunctionality. Here, we gift titanium-doped graphene (Ti-G), synthesized via plasma-more advantageous chemical vapor deposition (PECVD), as a next-era nanoplatform engineered for synergistic theranostic programs. Ti-G exhibits excessive biocompatibility (≥90% cellular viability at 2 hundred µg/mL), greater photothermal conversion performance (η = forty eight%), and intrinsic catalytic interest derived from Ti-precipitated lattice defects. These capabilities facilitate incredible doxorubicin loading capability (ninety five%) with pH-responsive release, and permit near-infrared (NIR)-mediated photoacoustic imaging and effective tumor ablation in murine fashions (tumor suppression: eighty% vs. Controls). Furthermore, Ti-G-based electrochemical biosensors done ultrasensitive detection of SARS-CoV-2 spike protein (LOD: 0.Five pg/mL), outperforming gold-based opposite numbers (LOD: 10 pg/mL). This twin-functionality encompassing both precision oncology and high-affinity viral biosensing positions Ti-G as a transformative cloth for customized nanomedicine. Our findings establish a scalable and clinically applicable nanoplatform with sturdy ability for integration into destiny biomedical technology.
Dr. Salah OUDJERTLI is a Senior Researcher Class (A) at the Research Center in Industrial Technologies in Algiers, Algeria, holding a Habilitation to Direct Research (HDR) in Materials Science. He is an active member of several research laboratories at Badji Mokhtar-Annaba University and numerous international scientific societies, including the ACS and APS. Dr. OUDJERTLI serves as a peer reviewer for prominent journals from IOPSCIENCE and AIP Publishing. His extensive research focuses on nanomaterials, ceramics, semiconductors, and 2D materials. An accomplished educator and prolific author, he has made significant contributions to the field through publications and international conference participation.
Copyright 2024 Mathews International LLC All Rights Reserved